NutraBrain at-home ketamine for chronic pain costs $425, then $69

NutraBrain at-home ketamine for chronic pain costs $425, then $69

UNITED STATES – November 14, 2026 -- Chronic pain patients in 15 US states can get ketamine therapy delivered to their door for $425 in the first month and $69 a month after that. NutraBrain Clinic, a telehealth provider, says it ships the medication by mail once its medical director, Dr. David Mahjoubi, has assessed a patient by video.

The price is for the clinic's Monthly Care plan. The first month covers the consultation and the medication. From month two, $69 a month covers ongoing care, including additional consultations and prescription adjustments. The monthly fee drops by $356 after the first month. Over 12 months, the listed prices add up to $1,184 ($425 plus 11 × $69), by our calculation.

The company has not said whether the $69 also covers medication after the first prescription, which NutraBrain pays for on Monthly Care.

Dr. Mahjoubi picks one of three formats after a video consultation

You start with an online intake form covering your pain history, treatments tried and current symptoms. Dr. Mahjoubi then assesses by video whether ketamine therapy suits you. Eligible patients receive medication from a licensed pharmacy partner and treat at home under a protocol he sets.

  • Ketamine nasal spray
  • Ketamine troches or rapidly dissolving tablets, taken under the tongue
  • Ketamine + Oxytocin nasal spray, which NutraBrain calls its exclusive formulation

He chooses the format based on the patient's condition, symptoms and previous treatments. The company says he has worked with ketamine therapy since 2014. It describes him as a board-certified anesthesiologist and president of the American Board of Ketamine Physicians.

The research NutraBrain cites covers infusions, not nasal sprays or troches

The company lists six conditions: neuropathic pain, complex regional pain syndrome (CRPS), fibromyalgia, chronic migraine, failed back surgery syndrome and long COVID pain. It says the evidence is limited for fibromyalgia and migraine, and that it is too early to say how much ketamine helps long COVID pain. It also says research on ketamine for chronic pain is still developing.

Three references are listed. A 2018 consensus guideline from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine and the American Society of Anesthesiologists covers intravenous ketamine infusions. The release describes it as showing moderate evidence for CRPS. A 2019 meta-analysis of randomized trials in Anesthesia and Analgesia is described as showing short-term pain reduction with IV ketamine in refractory chronic pain. The third, a 2011 paper in Pain, concerns central sensitization. None of the three addresses the nasal or under-the-tongue formats NutraBrain sells.

The company's other claims, such as reduced opioid needs for some patients and effects that outlast the medication, are attributed only to unspecified studies and clinical experience.

NutraBrain serves patients in Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts, New Jersey, New Mexico, New York, Texas, Utah, Virginia and Wisconsin.

Published by:
newsonline24_team
Markets